相关临床试验
17
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1912
已完成
7
41.2%
尚未招募
1
5.9%
招募中
6
35.3%
终止
1
5.9%
Unknown
2
11.8%
暂无批准数据
- ASBMB's weekly opportunities list features new meetings, awards, scholarships, and events for bioscience professionals, with member offerings prioritized. - Rice University's Future Leaders in Bioengineering Seminar Series invites postdoctoral fellows and senior Ph.D. students to apply by June 30, 2026, with travel and lodging support provided. - The U.S.–Chile Fulbright Antarctic Science Exchange will support approximately five early-career scientists for collaborative Antarctic research on extremophiles and molecular adaptation, with applications due September 15, 2026. - HHMI's Presidential Fellows Program offers a two- to three-year appointment for early-career professionals to work on strategic initiatives at HHMI headquarters in the Washington, D.C., area.
- Researchers at Rice University, Carnegie Mellon University, and Northwestern University have developed HOBIT, a wireless implantable device that generates oxygen locally to support high-density cell clusters for drug production. - The device achieved six times higher cell densities than conventional approaches and maintained 65% cell viability after 30 days compared to 20% in control devices without oxygenation. - HOBIT successfully produced three different biologic molecules simultaneously, including antibodies, hormones, and GLP-1-like molecules, demonstrating potential for treating multiple diseases including diabetes. - The compact, gum-sized device integrates an electrocatalytic oxygenator, battery, and electronics into a fully wireless system that can be remotely controlled and placed under the skin via minimally invasive surgery.
- Northwestern University researchers have developed HOBIT, an implantable device containing engineered cells that continuously produce multiple biologic drugs inside the body, including anti-HIV antibodies, diabetes treatments, and appetite-regulating hormones. - The device integrates oxygen-producing bioelectronics to overcome the critical challenge of cell survival in implants, achieving cell densities six times higher than conventional approaches and maintaining 65% cell viability after 30 days. - In animal studies, the gum-sized wireless device successfully delivered sustained levels of three different biologics with varying half-lives for 30 days, while control devices without oxygenation failed by day seven. - This breakthrough could transform chronic disease treatment by eliminating the need for patients to remember daily medications, with future applications planned for pancreatic cell therapies and larger animal model testing.
- Rice University bioengineer Omid Veiseh has secured a $2.2 million grant from the Bill and Melinda Gates Foundation to develop implantable cell factory platforms that deliver therapeutic antibodies continuously for two years or longer. - The innovative technology aims to address critical limitations of current monoclonal antibody treatments, which require frequent high-dose injections and create fluctuating drug levels that impact patient adherence and healthcare costs. - Two complementary strategies are being developed: hydrogel capsules for subcutaneous injection targeting seasonal malaria prophylaxis, and wireless miniaturized devices for continuous HIV-neutralizing antibody production over four years. - The project builds on successful preclinical studies that demonstrated stable, year-long in vivo delivery of HIV-neutralizing antibodies, with potential to transform global access to biologic therapies in resource-limited settings.
- Penn Medicine researchers are developing an innovative mRNA-based vaginal gel therapy to treat heavy menstrual bleeding, which affects one in three women and causes a woman to require blood transfusion every minute in the U.S. - The therapy uses lipid nanoparticles to deliver mRNA directly to endometrial tissue, targeting proteins involved in vasoconstriction and tissue repair pathways to reduce abnormal bleeding. - Wellcome Leap's Missed Vital Sign program is providing up to $5 million in funding, aiming to reduce treatment waiting times from the current average of five years to just five months. - The non-hormonal, at-home treatment represents a significant advancement over current limited options, which primarily include surgery and hormonal interventions with significant risks and side effects.
- RBL LLC announced the launch of Sentinel BioTherapeutics, a clinical-stage company developing innovative immune-priming therapies for solid tumors that typically respond poorly to checkpoint inhibitors. - The company's platform enables sustained local delivery of interleukin-2 (IL-2) through an allogeneic encapsulated cell-based system to enhance checkpoint inhibitor effectiveness against cancers like ovarian cancer and mesothelioma. - Phase 1 clinical data presented at the 2025 ASCO Annual Meeting demonstrate dose-dependent increases in CTLA-4 expression on T cells, supporting the therapy's potential as a priming agent for checkpoint inhibition. - Sentinel's lead program SENT001 holds fast-track designation for PROC and orphan disease designation for mesothelioma, with plans to initiate immune priming clinical trials for peritoneal solid tumors.
- Rice University researchers have developed an implantable "cytokine factory" that triggers potent immune responses against metastatic melanoma, pancreatic, and colorectal tumors by locally releasing interleukin-12. - The device works by recruiting specialized immune cells called precursor exhausted T cells, creating a durable population of tumor-targeting cells that showed efficacy in eliminating both local and distant tumors in preclinical models. - The technology demonstrated safety in both mouse and non-human primate models, with plans for an FDA investigational new drug application in early 2026 and the formation of a new biotech company.
- Researchers have developed a novel cancer therapy using near-infrared light to induce molecular vibrations that rupture cancer cell membranes. - In lab tests, this method eliminated 99% of human melanoma cells, with half of melanoma-afflicted mice experiencing complete remission. - The therapy utilizes aminocyanine molecules, commonly used in medical imaging, which vibrate when exposed to near-infrared light. - This approach offers a non-invasive method to target and destroy cancer cells, potentially revolutionizing cancer treatment.
- Rice University received a $34.9 million grant to develop ROGUE, a bioelectronic implant for type 2 diabetes and obesity treatment, designed to improve patient adherence. - ROGUE will house cells that produce therapies in response to the patient’s needs, offering a cost-effective alternative to frequent injections of biologics like GLP-1 RAs. - The implantable device will use closed-loop bioelectronics to monitor and adjust drug production, requiring only weekly recharging via a wearable device. - Clinical trials are planned to begin in the fifth year of the six-year project, aiming for rapid and cost-effective deployment via a minimally invasive outpatient procedure.
• AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors. • SWOG Cancer Research Network developed a risk prediction model to identify cancer patients at high risk for emergency room visits during clinical trials. • A national clinical trial is launched by UC San Francisco to repurpose existing drugs for treating traumatic brain injury (TBI), addressing a critical unmet need. • The Ohio State University initiates clinical trials for HOSU-53, a novel DHODH inhibitor, in partnership with Jabez Biosciences, targeting cancer metabolism.
